Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora, Inc. announced a planned leadership transition in its human resources organization. Executive Vice President and Chief Human Resources Officer Silvana Battaglia will retire from her role effective July 12, 2026, after a seven-year tenure, and continue as an advisor through the end of 2026. The company stated her decision was not due to any disagreement regarding operations, policies, or practices.
Samantha (Sam) Hammock will join Cencora as Executive Vice President and Chief Human Resources Officer effective July 13, 2026, reporting to CEO Bob Mauch and serving on the enterprise leadership team. She previously held senior HR roles at Verizon Communications and American Express. The press release highlights Cencora’s scale, including more than 51,000 team members, over $300 billion in annual revenue, and Fortune 500 and Global 500 rankings, underscoring the strategic importance of the CHRO role.
Cencora, Inc. announced that Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer, effective June 29, 2026, succeeding retiring CFO James F. Cleary, who will remain in an advisory role through the end of 2026. Boratto joins with extensive experience as former CFO of Bath & Body Works and CVS Health, and with prior senior finance roles at Merck.
Her employment package includes a $1,000,000 annual base salary, an annual bonus target equal to 100% of salary, a $2,000,000 cash sign-on bonus subject to repayment conditions, and a one-time restricted stock unit award valued at $6,000,000 with three-year ratable vesting. Cencora also reaffirmed its fiscal 2026 adjusted diluted EPS guidance range of $17.70 to $17.90, and its long-term targets of 7%–10% adjusted operating income growth and 10%–14% adjusted diluted EPS growth.
Cencora, Inc. director Dermot Mark Durcan reported an open-market purchase of 4,000 shares of Common Stock on 2026-05-28 at an average price of $266.26 per share. Following this transaction, he directly owns 27,767 Cencora shares.
Cencora reported strong quarterly growth for the period ended March 31, 2026. Revenue reached $78.4 billion, up 3.8% year over year, driven mainly by higher volumes in U.S. Healthcare Solutions, including GLP‑1 therapies for diabetes and weight loss, and growth in European distribution.
Profitability rose sharply. Net income attributable to Cencora increased to $1.64 billion from $718 million, with diluted EPS of $8.40 versus $3.68. Results benefited from a $1.09 billion gain on remeasuring the prior OneOncology stake and continued contributions from the 2025 RCA acquisition.
The balance sheet reflects aggressive investment. Total assets grew to $81.7 billion and goodwill to $16.45 billion, largely from the $7.39 billion OneOncology acquisition. Long‑term debt rose to $12.18 billion after multiple new term loans and senior notes, while cash and cash equivalents declined to $2.18 billion. Operating cash flow was a use of $966.5 million as working capital and acquisition‑related items absorbed cash.
Cencora reported solid fiscal 2026 second-quarter results with revenue of $78.4 billion, up 3.8% year-over-year. GAAP diluted EPS jumped to $8.40 from $3.68, boosted by a $1.1 billion gain tied to the OneOncology acquisition, while adjusted diluted EPS rose 7.5% to $4.75.
The company raised its fiscal 2026 adjusted EPS guidance to $17.65–$17.90 from $17.45–$17.75 and now expects about $3.0 billion in adjusted free cash flow. Management also plans to repurchase $1 billion of shares by the end of calendar 2026 and declared a quarterly dividend of $0.60 per share.
Tyler Lauren M reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. director Lauren M. Tyler received an equity award rather than making an open-market trade. On May 1, 2026, Tyler was granted 99 shares of Common Stock, reported at $304.00 per share, under the company’s Non-Employee Director Compensation Program.
The award represents restricted stock units granted in lieu of a $30,000 quarterly cash retainer, with actual receipt of the shares deferred until Tyler’s board service ends. After this grant, Tyler directly holds 3,809 shares of Cencora common stock, indicating this is a routine component of director compensation rather than a discretionary stock purchase or sale.
Cooper Ellen reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. director Ellen Cooper received an equity-based compensation award rather than cash. She was granted 99 shares of Common Stock on May 1, 2026, recorded at $304.00 per share, as a grant or award transaction.
According to the footnote, this is a grant of restricted stock units received in lieu of a $30,000 quarterly cash retainer under the company’s Non-Employee Director Compensation Program, with receipt of the shares deferred until she ceases board service. Following this award, she directly holds 796 shares of Cencora common stock.
NALLY DENNIS M reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. director Dennis M. Nally received an award of 116 shares of common stock on May 1, 2026. The shares were issued in lieu of a $35,000 quarterly cash retainer under the company’s Non-Employee Director Compensation Program.
Following this compensation grant, Nally directly holds 13,075 shares of Cencora common stock.
Cencora Inc reported that Vanguard Capital Management beneficially owned 14,210,260 shares of common stock, representing 7.3% of the class as reported on 03/31/2026. The filing shows sole voting power for 1,896,801 shares and sole dispositive power for 14,210,260 shares. The Schedule 13G filing was signed on 04/29/2026.
Krikorian Lazarus reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. reported that SVP & Chief Accounting Officer Lazarus Krikorian received a grant of 3,936 Restricted Stock Units on April 1, 2026. According to the filing, these Restricted Stock Units were received for no consideration and vest in full on April 1, 2028. Following this grant, Krikorian holds a total of 3,936 Restricted Stock Units directly.